Antifibrinolytic Agent – Mechanism, Uses and Drugs
An antifibrinolytic agent is a drug that inhibits the breakdown of blood clots, helping to stop or prevent excessive bleeding. It is commonly used in surgery, childbirth, and bleeding disorders.
Wissenswertes über "Antifibrinolytic Agent"
An antifibrinolytic agent is a drug that inhibits the breakdown of blood clots, helping to stop or prevent excessive bleeding. It is commonly used in surgery, childbirth, and bleeding disorders.
What is an Antifibrinolytic Agent?
An antifibrinolytic agent is a medication that inhibits fibrinolysis – the natural process by which the body dissolves blood clots. While fibrinolysis is an essential part of normal wound healing and vascular maintenance, it can become overactive in certain clinical conditions, leading to serious or life-threatening bleeding. Antifibrinolytic agents are used to control or prevent such bleeding by stabilizing existing clots.
Mechanism of Action
Blood clot formation and dissolution are carefully balanced processes. The enzyme plasmin plays a key role in clot breakdown by cleaving fibrin, the structural protein of a blood clot. Antifibrinolytic agents interfere with this process in different ways:
- Lysine analogues such as tranexamic acid and epsilon-aminocaproic acid competitively bind to plasminogen and plasmin, blocking their attachment to fibrin and thereby preventing clot dissolution.
- Aprotinin is a serine protease inhibitor that directly inhibits plasmin and also affects other components of the coagulation cascade.
The net effect is a stabilization of the blood clot and a reduction in bleeding tendency.
Indications – When Are Antifibrinolytics Used?
Antifibrinolytic agents are used across a broad range of clinical settings:
- Surgical procedures: Especially in cardiac surgery, orthopedic operations (e.g., hip or knee replacement), and liver surgery to reduce intraoperative blood loss.
- Obstetrics: To treat and prevent postpartum hemorrhage (bleeding after childbirth).
- Trauma: To reduce life-threatening bleeding in severely injured patients.
- Hemophilia and coagulation disorders: As adjunctive therapy in patients with inherited or acquired bleeding conditions.
- Heavy menstrual bleeding: Tranexamic acid is widely used for menorrhagia (abnormally heavy periods).
- Dental extractions: In patients with increased bleeding risk, such as those on anticoagulant therapy.
Key Active Substances
Tranexamic Acid
Tranexamic acid is the most widely used antifibrinolytic agent. It is available as tablets, intravenous solutions, and topical preparations. It is considered safe and well-tolerated, and is included on the World Health Organization (WHO) Model List of Essential Medicines.
Epsilon-Aminocaproic Acid
Epsilon-aminocaproic acid works similarly to tranexamic acid but is used less frequently and is not approved in all countries.
Aprotinin
Aprotinin (brand name: Trasylol) was widely used in cardiac surgery but was temporarily withdrawn from markets due to concerns about increased risks of kidney damage and cardiovascular events. It has since been reapproved in some countries under strict conditions.
Dosage and Administration
Dosage depends on the specific agent, the clinical indication, and the condition of the patient. For example, tranexamic acid is typically administered intravenously during surgery, while oral formulations are used for menorrhagia. Precise dosing should always be determined by qualified medical professionals.
Side Effects
Antifibrinolytic agents are generally well-tolerated. Possible side effects include:
- Nausea, vomiting, and diarrhea (especially with oral administration)
- Dizziness and headache
- Rarely: allergic reactions
- In cases of overdose or incorrect use: increased risk of thrombosis (formation of unwanted blood clots)
- Aprotinin specifically: increased risk of renal impairment and cardiovascular events
Contraindications
Antifibrinolytic agents should not be used, or used only with caution, in the following situations:
- Known hypersensitivity to the active substance
- Active thromboembolic events (e.g., pulmonary embolism, deep vein thrombosis)
- Severe renal impairment (dose adjustment required)
- Disseminated intravascular coagulation (DIC), unless concomitant heparin therapy is administered
References
- World Health Organization (WHO): WHO Model List of Essential Medicines, 23rd Edition, 2023. Available at: https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02
- Ker K, Edwards P, Perel P, Shakur H, Roberts I: Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ. 2012;344:e3054.
- Liumbruno GM, Bennardello F, Lattanzio A, et al.: Recommendations for the use of antifibrinolytic agents in surgery. Blood Transfus. 2011;9(4):383-401.
Best-selling products
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, probiotic lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryOligosaccharides
Sleep Cycle Optimization
Back Injuries
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Cologne list
Calorie content
Related search terms: Antifibrinolytic Agent + Antifibrinolytic + Antifibrinolytics